Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06192615 · ClinicalTrials.gov registry record · Phase 3
Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep (MINDDS II)
A Phase 3 study of Delirium, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,800
- Enrollment target
- 14
- Study locations
NCT06192615 is a Phase 3 study of Delirium that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 1,800 participants, above the 859-participant average among 62 other Delirium trials with a reported enrollment target (110% higher). The trial reports 14 study locations across 10 states.
The verdict
NCT06192615, a Phase 3 study of Delirium, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,800 participants
- Enrollment target
- 14
- Study locations
Study Summary
This is a pragmatic phase III, randomized, blinded, double placebo-controlled, three-arm trial of elderly patients following cardiac surgery to assess the relationship between nighttime intravenous (IV) and sublingual dexmedetomidine on postoperative delirium and functional outcomes after surgery.
Conditions Studied
Interventions
- DRUG Intravenous Dexmedetomidine
- DRUG Sublingual Dexmedetomidine
- DRUG Intravenous Placebo
- DRUG Sublingual Placebo
Study Locations (14)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Brigham and Women's Hospital - Boston
California
- Cedars-Sinai Medical Center - Los Angeles
- University of California San Francisco - San Francisco
New York
- Columbia University Medical Center - New York
- Montefiore Medical Center - The Bronx
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
Iowa
- University of Iowa Carver College of Medicine - Iowa City
Maryland
- University of Maryland School of Medicine - Baltimore
Missouri
- Washington University School of Medicine - St Louis
Nebraska
- University of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,800 participants |
| Start Date | 2025-01-06 |
| Est. Completion | 2029-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06192615
The ClinicalTrials.gov registry entry for NCT06192615 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,800 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 859-participant average among 62 other Delirium trials with a reported enrollment target (110% higher). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Delirium appearing as the primary indexed condition, and to 4 interventions - of which Intravenous Dexmedetomidine is the first listed.
NCT06192615 reports 14 study locations spanning 10 distinct geographic areas - top geographies include Massachusetts, California, New York.
Frequently Asked Questions
What is clinical trial NCT06192615 about?
NCT06192615 is a clinical study titled "Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep (MINDDS II)". This is a pragmatic phase III, randomized, blinded, double placebo-controlled, three-arm trial of elderly patients following cardiac surgery to assess the relationship between nighttime intravenous (IV) and sublingual dexmedetomidine on postoperative delirium and functional outcomes after surgery.
What is the current status of trial NCT06192615?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,800 participants. The study started on 2025-01-06. Estimated completion is 2029-03-31.
What conditions does trial NCT06192615 study?
This clinical trial studies the following conditions: Delirium.
What interventions are being tested in trial NCT06192615?
The interventions under investigation include: Intravenous Dexmedetomidine (DRUG), Sublingual Dexmedetomidine (DRUG), Intravenous Placebo (DRUG), Sublingual Placebo (DRUG).
Who is sponsoring clinical trial NCT06192615?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06192615 being conducted?
This trial has 14 study locations across California, Illinois, Iowa, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Delirium
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery
RECRUITING · Phase 3
-
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
RECRUITING · Phase 3
-
PANDORA: Delirium Prevention After Cardiac Surgery Using IV Acetaminophen to Prevent Postoperative Delirium in Older Cardiac Surgical Patients
ACTIVE NOT RECRUITING · Phase 3
-
The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure
COMPLETED · Phase 3
-
The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study
COMPLETED · Phase 3
-
Researching Efficient Approaches to Delirium Identification-Sustaining Effective Translation
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.